First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

RCT (n=1,581) demonstrated improved overall survival (median 13.1 vs 11.1 months; HR, 0.71; 98.4% CI 0.59–0.86]; p<0.001) and progression free survival (HR 0.68; CI 0.56–0.81; p<0.0001) with nivolumab with chemotherapy versus chemotherapy alone in this setting.

Source:

The Lancet